The theme of the overall program focuses on development of a broad spectrum vaccine technology process employing immunoinformatics tools for epitope prediction. Many of the processes and procedures to be employed by projects within the program employ human leucocytes, HLA transgenic mice, and assays for characterization of cell mediated immune responses to verify the in silico predictions and to analyze immune responses engendered by vaccine candidates. This cell mediated immunity scientific core is designed to provide the equipment, staffing, and capabilities required to support these verification processes and analyses. All research and technology development projects within the program specify that some or all of the resources provided by this core will be employed by each project. The core capabilities and infrastructure provided by this core will include the following: 1) Flow cytometric and cytokine bead analysis 2) ELISpot assay analysis 3) Human leucocyte cryopreservation and short term storage 4) Insuring program access to required HLA transgenic mice through support of HLA transgenic murine breeding colony at Taconic Farms

Public Health Relevance

The work proposed addresses the need to develop vaccines against chronic HCV, H. pylori, Tularemia, Burkholderia species, and tick bourne diseases, and will provide shared core instrumentation and technical support for projects addressing these applications. Immune responses elicited by antigens and vaccine candidates directed against these pathogens will be measured using both human and murine leucocytes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082642-05
Application #
8501262
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$312,914
Indirect Cost
$66,738
Name
University of Rhode Island
Department
Type
DUNS #
144017188
City
Kingston
State
RI
Country
United States
Zip Code
02881
De Groot, Anne S; Ross, Ted M; Levitz, Lauren et al. (2015) C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells. Immunol Cell Biol 93:189-97
Zhang, Songhua; Desrosiers, Joseph; Aponte-Pieras, Jose R et al. (2014) Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. PLoS One 9:e94974
Dalal, Rahul S; Moss, Steven F (2014) At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol 96:213-24
Bailey-Kellogg, Chris; Gutiérrez, Andres H; Moise, Leonard et al. (2014) CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnol Bioeng 111:2170-82
Mishra, Sasmita; Lavelle, Bianca J; Desrosiers, Joe et al. (2014) Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice. PLoS One 9:e104606
Pichu, Sivakamasundari; Ribeiro, Jose M C; Mather, Thomas N et al. (2014) Purification of a serine protease and evidence for a protein C activator from the saliva of the tick, Ixodes scapularis. Toxicon 77:32-9
Mishra, Sasmita; Losikoff, Phyllis T; Self, Alyssa A et al. (2014) Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells. Vaccine 32:3285-92
Spero, Denice; Levitz, Lauren; De Groot, Anne S (2013) Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference. Hum Vaccin Immunother 9:1555-7
De Groot, Anne S; Ardito, Matthew; Terry, Frances et al. (2013) Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother 9:950-6
Koch, Manuel; Meyer, Thomas F; Moss, Steven F (2013) Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter 18 Suppl 1:18-23

Showing the most recent 10 out of 25 publications